Thomas Helleday

36.1k citations
264 papers · 22.3k · 6 hit papers · h-index 69

Impact in

  • Oncology top 0.05%
    • PARP inhibition in cancer therapy
    • Cancer-related Molecular Pathways
    • Carcinogens and Genotoxicity Assessment

Papers in

    • DNA Repair Mechanisms 154
    • CRISPR and Genetic Engineering 34
    • Cancer therapeutics and mechanisms 27
    • Biochemical and Molecular Research 19
    • PARP inhibition in cancer therapy 55
    • Cancer-related Molecular Pathways 26

Thomas Helleday

264 papers receiving 22.1k citations

Thomas Helleday's Hit Papers

Mechanisms underlying mutational signatures in human cancers 2014 · 558 citations
5580+7+14Years since publication10002.0k3.0k

Peers

Thomas Helleday
Comparison fields: 5 of 154
  • Oncology 9.6k
  • Cancer Research 3.7k
  • Molecular Biology 16.8k
  • Cell Biology 1.6k
  • Genetics 1.9k
Replace Shunichi Takeda with:
Shunichi Takeda Japan
Varda Rotter Israel
Joyce M. Slingerland United States
André Nussenzweig United States
Christopher J. Lord United Kingdom
Andrew L. Kung United States
Weiya Xia United States
Paul Dent United States
Owen J. Sansom United Kingdom
Jane B. Trepel United States
Thomas Helleday relative to Shunichi Takeda Japan Shunichi Takeda's profile →
Citations per field
00.5×1.6×
Shunichi Takeda · 1×
Citations per year

Countries citing papers authored by Thomas Helleday

Since Specialization
Citations

This map shows the geographic impact of Thomas Helleday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Helleday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Helleday more than expected).

Fields of papers citing papers by Thomas Helleday

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Helleday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Helleday. The network helps show where Thomas Helleday may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Helleday, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Helleday Line = papers co-authored together Thomas Helleday links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 264 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Hit paper breakdown →
20053823
2
DNA repair pathways as targets for cancer therapy
Hit paper breakdown →
20081317
3
Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair
Hit paper breakdown →
2010649
4
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Hit paper breakdown →
2011615
5
Mechanisms underlying mutational signatures in human cancers
Hit paper breakdown →
2014558
6
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Hit paper breakdown →
2005514
7 2009483
8 2007465
9 2005433
10 2018363
11 2010362
12 2005359
13 2013355
14 2014344
15 2001325
16 2014301
17 2010281
18 2012276
19 2005272
20 2003250

About Thomas Helleday

Thomas Helleday is a scholar working on Molecular Biology, Oncology, Cancer Research, Cell Biology and Pulmonary and Respiratory Medicine, having authored 264 papers that have together received 22.3k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (154 papers), PARP inhibition in cancer therapy (55 papers), CRISPR and Genetic Engineering (34 papers), Carcinogens and Genotoxicity Assessment (28 papers), Cancer therapeutics and mechanisms (27 papers), Cancer-related Molecular Pathways (26 papers), Microtubule and mitosis dynamics (25 papers) and Biochemical and Molecular Research (19 papers). The work is most often cited by research in Oncology (9.6k citations), Cancer Research (3.7k citations), Molecular Biology (16.8k citations), Cell Biology (1.6k citations) and Genetics (1.9k citations). Thomas Helleday has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Niklas Schultz, Eva Petermann, Helen E. Bryant, Cecilia Lundin, Mark Meuth, Suzanne Kyle, Huw D. Thomas, Nicola J. Curtin, Elena López‐Knowles and Ricky A. Sharma. Their work appears in journals such as Nucleic Acids Research, Cancer Research, DNA repair, Journal of Molecular Biology and Molecular Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact